Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company whose news flow centers on cancer drug development, regulatory milestones, and commercialization updates. The company’s announcements emphasize progress with its two FDA-approved therapies: Revuforj® (revumenib), an oral menin inhibitor for specific relapsed or refractory acute leukemias, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor-blocking antibody for chronic graft-versus-host disease after at least two prior systemic therapies.
News for SNDX often covers quarterly and annual financial results, product revenue trends for Revuforj and Niktimvo, and guidance on research and development as well as selling, general and administrative expenses. Investors can follow updates on clinical trial milestones, such as Phase 2 and Phase 3 studies of revumenib in newly diagnosed and relapsed or refractory NPM1-mutated and KMT2A-rearranged AML, and trials of axatilimab in chronic GVHD and idiopathic pulmonary fibrosis.
Press releases also highlight regulatory events, including FDA approvals and label expansions, inclusion of revumenib in clinical practice guidelines, and special designations such as Orphan Drug, Fast Track, and Breakthrough Therapy. Scientific and medical conference activity is another recurring theme, with multiple abstracts and oral presentations at meetings like the American Society of Hematology and appearances at investor conferences and healthcare forums.
In addition, Syndax issues news on collaborations and access initiatives, such as its agreement with the World Orphan Drug Alliance to launch a multi-regional Managed Access Program for Revuforj outside the United States. For investors and observers tracking SNDX, the news stream provides insight into commercial performance, pipeline evolution, partnership activity, and the company’s stated path toward profitability.
Summary not available.
Summary not available.
Summary not available.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, announced an inducement stock option grant for its new President, Dr. Neil Gallagher. Effective April 10, 2023, Dr. Gallagher received an award to purchase 250,000 shares at an exercise price of $19.35, the closing stock price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on Dr. Gallagher's continued employment. This grant was approved by Syndax's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4). Syndax's innovative pipeline includes drugs like revumenib and axatilimab, which are in pivotal trials. Further details can be found on their official website.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a biopharmaceutical company focused on cancer therapies, announced on April 3, 2023, the granting of inducement awards to six new employees under its 2023 Inducement Plan. These awards total 121,100 shares of common stock, with an exercise price set at $20.91 per share, reflecting the closing stock price on that date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent upon the employees’ continued service. Syndax's notable pipeline includes revumenib and axatilimab, both currently in pivotal trials.
Syndax Pharmaceuticals (Nasdaq: SNDX) has appointed Neil Gallagher, M.D., Ph.D., as President and Head of Research and Development, effective April 10, 2023. With over 20 years in oncology drug development, including roles at AbbVie and Novartis, Gallagher aims to enhance the company’s pipeline, notably revumenib and axatilimab, both in pivotal trials. CEO Michael A. Metzger praised Gallagher's experience, particularly in securing drug approvals. The transition follows the prior president's shift to the Board of Directors, indicating a strategy for growth and innovation in targeted oncology.
Syndax Pharmaceuticals (SNDX) announced the publication of Phase 1 data from its AUGMENT-101 trial of revumenib for treating nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory acute leukemia in Nature. The study involved 68 patients, with 60 evaluable for efficacy. Results showed a 53% overall response rate (32/60) and 30% CR/CRh (18/60). Revumenib was well-tolerated, with no treatment-related discontinuations. The company anticipates topline data from the pivotal trial by Q3 2023 and plans to file a New Drug Application by year-end, potentially positioning revumenib as the first approved menin inhibitor.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) announced on March 6, 2023, the granting of stock options for 15,200 shares to a new employee under their 2023 Inducement Plan. The options have an exercise price of $24.86, closing on March 1, 2023. The vesting schedule includes 25% vesting on the one-year anniversary, with the remaining shares vesting monthly over three years, contingent upon continued employment. Syndax focuses on developing cancer therapies including innovative drugs like revumenib and axatilimab, which are currently in pivotal trials.
Syndax Pharmaceuticals reported significant advancements in its clinical trials and a financial update for Q4 and full-year 2022. Key highlights include anticipated topline data from the AUGMENT-101 trial for revumenib expected in Q3 2023 and from the AGAVE-201 trial for axatilimab expected mid-2023. The company is on track to submit two U.S. regulatory filings by the end of 2023. Financially, Syndax reported a net loss of $39.2 million for Q4 2022 and $149.3 million for the full year. The company had cash reserves totaling $481.3 million as of year-end 2022, which supports ongoing R&D activities.
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced that it will report its fourth quarter and year-end 2022 financial results on February 28, 2023, after the U.S. market close. The management will conduct a conference call and live audio webcast at 4:30 p.m. ET the same day to discuss these results and provide a business update. Investors can access the webcast through the company's website and a replay will be available 24 hours after the call for 90 days. Syndax is focused on developing cancer therapies, with its pipeline including revumenib and axatilimab, which are in pivotal trials.